IndexBox 10月11日发布全球神经外科机器人手术系统市场报告，覆盖2026至2035年的预测。报告的核心判断是，这个市场进入2026年时，需求基本面更广、采购行为更规范、供应架构在区域上更多元。市场正在进入一个持续扩张阶段，支撑它的是复杂神经和脊柱疾病患病率的增长，以及颅脑和脊柱手术对精度的临床需求。这些计算机辅助机器人系统增强了精度、稳定性和可视化，正在被医院资本采购委员会、门诊手术中心和研究机构越来越多地采用。
IndexBox released a global neurosurgery robotic surgical systems market report on October 11, covering forecasts from 2026 to 2035. The report's core judgment is that the market enters 2026 with broader demand fundamentals, more disciplined procurement behavior, and a more regionally diversified supply architecture. The market is entering a phase of sustained expansion, supported by the growing prevalence of complex neurological and spinal disorders and clinical demand for precision in cranial and spinal procedures. These computer-assisted robotic systems enhance precision, stability, and visualization, and are increasingly adopted across hospital capital procurement committees, ambulatory surgery centers, and research institutions.
市场按设备类型、临床应用、护理环境、工作流阶段、技术、监管类别和服务模式细分。需求集中在精准颅脑肿瘤切除、脊柱融合和深部脑刺激，术前规划和模拟是一个关键工作流阶段。装机量动态、替换周期和软件升级正在塑造售后经济。监管路径，特别是FDA 510(k)和De Novo分类，影响产品时间线和竞争定位。供应链韧性依赖于高精度执行器、传感器和专有软件控制的子系统。竞争格局同时包含成熟医疗器械集团和专业机器人手术公司，战略合作和收购推动整合。随着医疗系统优先考虑微创技术和价值导向医疗，神经外科机器人系统的采用预计到2035年加速，新兴市场贡献增长。
The market is segmented by device type, clinical application, care setting, workflow stage, technology, regulatory class, and service model. Demand is concentrated in precision cranial tumor resection, spinal fusion, and deep brain stimulation, with pre-operative planning and simulation representing a critical workflow stage. Installed-base dynamics, replacement cycles, and software upgrades are shaping aftermarket economics. Regulatory pathways, particularly FDA 510(k) and De Novo classifications, influence product timelines and competitive positioning. Supply chain resilience depends on high-precision actuators, sensors, and proprietary software-controlled subsystems. The competitive landscape features both established medical device conglomerates and specialized robotic surgery firms, with strategic partnerships and acquisitions driving consolidation. As healthcare systems prioritize minimally invasive techniques and value-based care, the adoption of neurosurgery robotic systems is expected to accelerate through 2035, with emerging markets contributing to growth.
基准情景下，2026至2035年神经外科机器人手术系统市场预计以8.2%的年复合增长率扩张，到2035年达到市场指数220（2025年等于100）。增长由机器人精度技术进步、AI和机器学习在外科规划中的整合，以及微创神经外科手术采用率上升驱动。北美和欧洲预计保持显著份额，因为医疗基础设施先进、报销政策有利，而亚太地区预计增长最快，受医疗可及性改善和手术量上升推动。市场面临高端资本成本、训练有素的神经外科医生有限、监管审批严格等制约，这可能在某些地区放缓增长。但正在进行的临床试验和在儿科神经外科、癫痫手术中扩展的应用，呈现新的机会。竞争格局可能加剧，主要参与者投资研发和战略合作，以增强产品组合和地理覆盖。
In the baseline scenario, the neurosurgery robotic surgical systems market from 2026 to 2035 is projected to expand at a compound annual growth rate of 8.2%, reaching a market index of 220 by 2035 (2025=100). This growth is driven by technological advancements in robotic precision, integration of AI and machine learning for surgical planning, and rising adoption of minimally invasive neurosurgical procedures. North America and Europe are expected to maintain significant shares due to advanced healthcare infrastructure and favorable reimbursement policies, while Asia-Pacific is anticipated to witness the fastest growth, fueled by improving healthcare access and rising surgical volumes. The market faces restraints such as high capital costs, limited trained neurosurgeons, and stringent regulatory approvals, which may moderate growth in certain regions. However, ongoing clinical trials and expanding applications in pediatric neurosurgery and epilepsy surgery present new opportunities. The competitive landscape is likely to intensify, with key players investing in R&D and strategic collaborations to enhance product portfolios and geographic reach.
需求结构按终端使用行业划分：医院占约65%，门诊手术中心占15%，研究和学术机构占10%，专科神经外科诊所占7%，政府、军队等占3%。医院是最大的终端使用部门，占安装量和手术的大部分。需求主要由复杂颅脑和脊柱手术对精度的需求驱动，机器人辅助增强了准确性、减少了震颤、改善了可视化。医院资本采购委员会正在越来越多地为这些系统分配预算，支持它的是并发症率降低和住院时间缩短的证据。到2035年，向价值导向医疗和微创技术的转变将进一步推动采用。关键需求侧指标包括神经外科手术数量、医院资本支出预算和训练有素的神经外科医生的可用性。旧系统的替换周期和向软件增强平台的升级也将贡献持续需求。主要医院和学术医疗中心预计在采用具有集成AI和成像能力的下一代系统方面领先。
Demand structure by end-use industry: hospitals account for about 65%, ambulatory surgery centers 15%, research and academic institutions 10%, specialty neurosurgery clinics 7%, and government, military, etc. 3%. Hospitals represent the largest end-use sector, accounting for the majority of installations and procedures. Demand is primarily driven by the need for precision in complex cranial and spinal surgeries, where robotic assistance enhances accuracy, reduces tremor, and improves visualization. Hospital capital procurement committees are increasingly allocating budgets for these systems, supported by evidence of reduced complication rates and shorter hospital stays. Through 2035, the shift toward value-based care and minimally invasive techniques will further propel adoption. Key demand-side indicators include the number of neurosurgical procedures, hospital capital expenditure budgets, and the availability of trained neurosurgeons. The replacement cycle for older systems and the upgrade to software-enhanced platforms will also contribute to sustained demand. Major hospitals and academic medical centers are expected to lead in adopting next-generation systems with integrated AI and imaging capabilities.
区域动态方面，亚太占约30%，预计增长最快；北美占35%，保持最大份额；欧洲占20%，重点在微创手术和协作研究；拉丁美洲占8%，是新兴市场；中东和非洲占7%，主要是富裕海湾国家投资先进医疗。报告列出了25家关键市场参与者，包括直觉外科、美敦力、史赛克、Zimmer Biomet、Brainlab、Globus Medical、西门子医疗、Synaptive Medical、Renishaw、Curexo、Accuray、B. Braun、强生（DePuy Synthes）、Smith & Nephew、Karl Storz、OmniGuide、Monteris Medical、Aesculap、Collin Medical、Medicaroid、Avatera Medical、CMR Surgical、Asensus Surgical、Precision Neuroscience和Surgical Theater。这份名单里有做软组织手术的直觉外科，有做脊柱和颅脑导航的美敦力，有做骨科机器人向脊柱扩展的史赛克，也有做神经接口的初创公司Precision Neuroscience。
On regional dynamics, Asia-Pacific accounts for about 30% and is expected to grow fastest; North America 35%, maintaining the largest share; Europe 20%, focused on minimally invasive surgery and collaborative research; Latin America 8%, an emerging market; Middle East & Africa 7%, mainly wealthy Gulf countries investing in advanced healthcare. The report lists 25 key market participants, including Intuitive Surgical, Medtronic, Stryker, Zimmer Biomet, Brainlab, Globus Medical, Siemens Healthineers, Synaptive Medical, Renishaw, Curexo, Accuray, B. Braun, Johnson & Johnson (DePuy Synthes), Smith & Nephew, Karl Storz, OmniGuide, Monteris Medical, Aesculap, Collin Medical, Medicaroid, Avatera Medical, CMR Surgical, Asensus Surgical, Precision Neuroscience, and Surgical Theater. This list includes Intuitive Surgical in soft tissue surgery, Medtronic in spine and cranial navigation, Stryker expanding from orthopedic robotics into spine, and startup Precision Neuroscience in neural interfaces.
把这份报告和前面讨论的手术机器人内容放在一起看，神经外科机器人这个细分市场的位置会更清楚。Medtech Insight报道过MMI的显微外科机器人拿到1.25亿美元D轮，要拿显微外科的精度去碰阿尔茨海默病。MassDevice报道过Butterfly Network和Bridge Neurotech用超声做非侵入式脑机接口。这些都是在神经科学和精密操作交叉地带的新尝试。IndexBox这份报告覆盖的是更成熟的市场：已经在医院里做颅脑肿瘤切除、脊柱融合、深部脑刺激的手术机器人。这个市场的增速8.2%，比人形机器人、具身智能这些热门赛道的增速要低，但它的客户是医院，付费能力明确，监管路径清晰，商业模式经过验证。这是一条慢但稳的赛道，和前面那些高增长高不确定性的赛道形成对比。
Placing this report alongside the surgical robotics content discussed earlier makes the position of the neurosurgery robotics niche clearer. Medtech Insight reported on MMI's microsurgery robot raising a $125 million Series D, bringing microsurgical precision to Alzheimer's disease. MassDevice reported on Butterfly Network and Bridge Neurotech using ultrasound for non-invasive brain-computer interfaces. These are new attempts at the intersection of neuroscience and precision manipulation. IndexBox's report covers a more mature market: surgical robots already in hospitals performing cranial tumor resection, spinal fusion, and deep brain stimulation. This market's 8.2% growth rate is lower than hot tracks like humanoid robots and embodied intelligence, but its customers are hospitals, with clear payment capacity, clear regulatory pathways, and validated business models. This is a slow but steady track, contrasting with the high-growth, high-uncertainty tracks discussed earlier.
